Clinical Trial Update: An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (0683-016)(TERMINATED) [Phase 1]

View source ↗

Summary

Terminated Phase 1 study evaluating an HDAC inhibitor plus Targretin (bexarotene) in patients with cutaneous T-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma

Drugs mentioned

• HDAC inhibitor (histone deacetylase inhibitor)
• Targretin (bexarotene)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Lymphoma | Phase 1 | Status: TERMINATED | Results posted: 2009-08-14